290 related articles for article (PubMed ID: 32306243)
1. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review.
Dal Bello G; Gisondi P; Idolazzi L; Girolomoni G
Rheumatol Ther; 2020 Jun; 7(2):271-285. PubMed ID: 32306243
[TBL] [Abstract][Full Text] [Related]
2. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions.
Xue Y; Jiang L; Cheng Q; Chen H; Yu Y; Lin Y; Yang X; Kong N; Zhu X; Xu X; Wan W; Zou H
PLoS One; 2012; 7(10):e46740. PubMed ID: 23144698
[TBL] [Abstract][Full Text] [Related]
3. Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "sine psoriasis".
Caso F; Postiglione L; Covelli B; Ricciardone M; Di Spigna G; Formisano P; D'Esposito V; Girolimetto N; Tasso M; Peluso R; Navarini L; Ciccozzi M; Margiotta DPE; Oliviero F; Afeltra A; Punzi L; Del Puente A; Scarpa R; Costa L
Clin Rheumatol; 2019 Sep; 38(9):2547-2552. PubMed ID: 31147798
[TBL] [Abstract][Full Text] [Related]
4. Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Wang CR; Tsai HW
World J Diabetes; 2021 Mar; 12(3):238-260. PubMed ID: 33758645
[TBL] [Abstract][Full Text] [Related]
5. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity.
Eder L; Jayakar J; Pollock R; Pellett F; Thavaneswaran A; Chandran V; Rosen CF; Gladman DD
Ann Rheum Dis; 2013 Dec; 72(12):1956-61. PubMed ID: 23243196
[TBL] [Abstract][Full Text] [Related]
6. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A
J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001
[TBL] [Abstract][Full Text] [Related]
7. Apremilast for the treatment of psoriatic arthritis.
Souto A; Gómez-Reino JJ
Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
[TBL] [Abstract][Full Text] [Related]
8. Update on the treatment of psoriasis and psoriatic arthritis - role of apremilast.
Forchhammer S; Ghoreschi K
Psoriasis (Auckl); 2015; 5():117-124. PubMed ID: 29387588
[TBL] [Abstract][Full Text] [Related]
9. Circulating Mir-140 and leptin improve the accuracy of the differential diagnosis between psoriatic arthritis and rheumatoid arthritis: a case-control study.
Cheleschi S; Tenti S; Bedogni G; Fioravanti A
Transl Res; 2022 Jan; 239():18-34. PubMed ID: 34380068
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report.
Gualtierotti R; De Lucia O
J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30909370
[TBL] [Abstract][Full Text] [Related]
11. Apremilast and its role in psoriatic arthritis.
Sandhu VK; Eder L; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity.
Dikbas O; Tosun M; Bes C; Tonuk SB; Aksehirli OY; Soy M
Int J Rheum Dis; 2016 Jul; 19(7):672-7. PubMed ID: 25196858
[TBL] [Abstract][Full Text] [Related]
13. Obesity and Psoriatic Arthritis: A Narrative Review.
Kumthekar A; Ogdie A
Rheumatol Ther; 2020 Sep; 7(3):447-456. PubMed ID: 32495313
[TBL] [Abstract][Full Text] [Related]
14. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management.
Russolillo A; Iervolino S; Peluso R; Lupoli R; Di Minno A; Pappone N; Di Minno MN
Rheumatology (Oxford); 2013 Jan; 52(1):62-7. PubMed ID: 22989426
[TBL] [Abstract][Full Text] [Related]
15. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Palfreeman AC; McNamee KE; McCann FE
Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic Treatment Strategies in Psoriatic Arthritis.
Ayan G; Ribeiro A; Macit B; Proft F
Clin Ther; 2023 Sep; 45(9):826-840. PubMed ID: 37455227
[TBL] [Abstract][Full Text] [Related]
17. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.
Mease PJ; Armstrong AW
Drugs; 2014 Mar; 74(4):423-41. PubMed ID: 24566842
[TBL] [Abstract][Full Text] [Related]
18. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
19. Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.
Mease PJ
Rheumatol Ther; 2014 Dec; 1(1):1-20. PubMed ID: 27747762
[TBL] [Abstract][Full Text] [Related]
20. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
